drchrono releases API for developers

Article

Drchrono, Inc. recently launched its application programming interface (API) that will allow developers to build their own healthcare applications.

Mountain View, CA-Drchrono, Inc., the creator of a free electronic medical record (EMR) platform on the iPad, iPhone, and cloud, recently released its application programming interface (API)
 that will allow developers to build their own healthcare applications on top of the drchrono platform.

Only 1.3% of APIs listed on ProgrammableWeb, an API database, are associated with the medical services sector. Innovators have avoided developing applications for the healthcare industry due to high regulations and the difficulty in accessing APIs from health institutions. Drchrono wants to ease developers’ requests to the API as easy as a sign-up and one-week review process. Drchrono would like to encourage developers to find opportunities in the evolving healthcare space to launch new companies. The current procedure for accessing a health institution’s API involves working with the organization’s business development team, a potentially lengthy process. Because each institution uses its own API, it can be a very time consuming process for companies to access it. By leveraging drchrono, these organizations can access their patients’ information for application construction within a week. 

Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.